Daiichinkyo Co (STU:D4S) Asset Impairment Charge : €0 Mil (TTM As of Sep. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Asset Impairment Charge?

Daiichinkyo Co's Asset Impairment Charge for the three months ended in Sep. 2024 was €0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 was €0 Mil.

Daiichinkyo Co Asset Impairment Charge Historical Data

The historical data trend for Daiichinkyo Co's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Asset Impairment Charge Chart

Daiichinkyo Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Asset Impairment Charge

Get a 7-Day Free Trial

Daiichinkyo Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Daiichinkyo Co Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

Daiichinkyo Co Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (STU:D4S) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

DSNKY:USA DSKYF:USA 4568:Mexico 4568:Japan

Address

3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426

Website

https://www.daiichisankyo.com

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co Headlines

No Headlines